

## Publikationen 2009

### Originalarbeiten

1. Ampollini L, Soltermann A, Felley-Bosco E, Lardinois D, Arni S, Speck RF, Weder W, Opitz I. Immuno-chemotherapy reduces recurrence of malignant pleural mesothelioma: an experimental setting. *Eur J Cardiothorac Surg* 2009;35(3):457-62.
2. Baenziger S, Heikenwalder M, Johansen P, Schlaepfer E, Hofer U, Miller RC, Diemand S, Honda K, Kundig TM, Aguzzi A, Speck RF. Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology. *Blood* 2009;113(2):377-88.
3. Ballif M, Ledergerber B, Battegay M, Cavassini M, Bernasconi E, Schmid P, Hirschel B, Furrer H, Rickenbach M, Opravil M, Weber R. Swiss HIV Cohort Study. Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. *PLoS One* 2009;4(12):e8275.
4. Bellini, C., Keiser, O., Chave, J. P., Evison, J., Fehr, J., Kaiser, L., Weber, R., Vernazza, P., Bernasconi, E., Telenti, A. and Cavassini, M. Liver enzyme elevation after lamivudine withdrawal in HIV-hepatitis B virus co-infected patients: the Swiss HIV Cohort Study. *HIV Med* 2009; 10(1):12-18.
5. Bihl F, Berger C, Chisholm JV, 3rd, Henry LM, Bertisch B, Trojan A, Nadal D, Speck RF, Flepp M, Brander C, Mueller NJ. Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma. *AIDS* 2009;23(14):1918-22.
6. Clifford GM, Rickenbach M, Lise M, Dal Maso L, Battegay M, Bohlius J, Boffi El Amari E, Karrer U, Jundt G, Bordoni A, Ess S, Franceschi S. Hodgkin lymphoma in the Swiss HIV Cohort Study. *Blood* 2009;113(23):5737-42.
7. Combescure C, Vallier N, Ledergerber B, Cavassini M, Furrer H, Rauch A, Battegay M, Bernasconi E, Vernazza P, Hirschel B. How reliable is an undetectable viral load? *HIV Med* 2009;10(8):470-6.
8. Conen A, Fehr J, Glass TR, Furrer H, Weber R, Vernazza P, Hirschel B, Cavassini M, Bernasconi E, Bucher HC, Battegay M. Self-reported alcohol consumption and its association with adherence and outcome of antiretroviral therapy in the Swiss HIV Cohort Study. *Antivir Ther* 2009;14(3):349-57.
9. Dang T, Jatton-Ogay K, Flepp M, Kovari H, Evison JM, Fehr J, Schmid P, Boffi El Amari E, Cavassini M, Odorico M, Tarr PE, Greub G. High prevalence of anorectal chlamydial infection in HIV-infected men who have sex with men in Switzerland. *Clin Infect Dis* 2009;49(10):1532-5.
10. di Iulio J, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, Furrer H, Gunthard HF, Colombo S, Csajka C, Eap CB, Decosterd LA, Telenti A. In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function. *Pharmacogenet Genomics* 2009;19(4):300-9.

11. Dorner M, Brandt S, Tinguely M, Zucol F, Bourquin JP, Zauner L, Berger C, Bernasconi M, Speck RF, Nadal D. Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production. *Immunology* 2009;128(4):573-9.
12. Dunn D, von Wyl V, Price H, Asboe D. The impact of the 0-0 cell on measures of amino acid covariation. *AIDS* 2009 [Epub ahead of print].
13. Elzi L, Kaufmann G, Weber R, Fux CA, Cavassini M, Hirschel B, Vernazza P, Bernasconi E, Battegay M. Discontinuation of enfuvirtide in heavily pretreated HIV-infected individuals. *HIV Clin Trials* 2009;10(4):207-14.
14. Fayet A, Beguin A, Zanolari B, Cruchon S, Guignard N, Telenti A, Cavassini M, Gunthard HF, Buclin T, Biollaz J, Rochat B, Decosterd LA. A LC-tandem MS assay for the simultaneous measurement of new antiretroviral agents: Raltegravir, maraviroc, darunavir, and etravirine. *J Chromatogr B Analyt Technol Biomed Life Sci* 2009;877(11-12):1057-69.
15. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, Castagna A, Cozzi-Lepri A, De Luca A, Easterbrook P, Gunthard HF, Mallal S, Mussini C, Dalmau J, Martinez-Picado J, Miro JM, Obel N, Wolinsky SM, Martinson JJ, Detels R, Margolick JB, Jacobson LP, Descombes P, Antonarakis SE, Beckmann JS, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Feng S, Telenti A, Goldstein DB. Common genetic variation and the control of HIV-1 in humans. *PLoS Genet* 2009;5(12):e1000791.
16. Flammer AJ, Vo NT, Ledergerber B, Hermann F, Gamperli A, Huttner A, Evison J, Baumgartner I, Cavassini M, Hayoz D, Quitzau K, Hersberger M, Sudano I, Ruschitzka F, Luscher TF, Noll G, Weber R. Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. *Heart* 2009;95(5):385-90.
17. Gaspert A, Luthi B, Mueller NJ, Bossart W, Heim A, Wuthrich RP, Fehr T. Subacute allograft failure with dysuria and hematuria in a kidney transplant recipient. *Am J Kidney Dis* 2009;54(1):154-8.
18. Gaudieri S, Rauch A, Pfafferott K, Barnes E, Cheng W, McCaughan G, Shackel N, Jeffrey GP, Mollison L, Baker R, Furrer H, Gunthard HF, Freitas E, Humphreys I, Klenerman P, Mallal S, James I, Roberts S, Nolan D, Lucas M. Hepatitis C virus drug resistance and immune-driven adaptations: relevance to new antiviral therapy. *Hepatology* 2009;49(4):1069-82.
19. Ghielmetti M, Millard AL, Haeberli L, Bossart W, Seebach JD, Schneider MK, Mueller NJ. Human CMV infection of porcine endothelial cells increases adhesion receptor expression and human leukocyte recruitment. *Transplantation* 2009;87(12):1792-800.
20. Gianella S, Haeberli L, Joos B, Ledergerber B, Wuthrich RP, Weber R, Kuster H, Hauser PM, Fehr T, Mueller NJ. Molecular evidence of interhuman transmission in an outbreak of *Pneumocystis jirovecii* pneumonia among renal transplant recipients. *Transpl Infect Dis* 2009. [Epub ahead of print]

21. Glass TR, Battegay M, Cavassini M, De Geest S, Furrer H, Vernazza PL, Hirschel B, Bernasconi E, Rickenbach M, Gunthard HF, Bucher HC. Longitudinal Analysis of Patterns and Predictors of Changes in Self-Reported Adherence to Antiretroviral Therapy: Swiss HIV Cohort Study. *J Acquir Immune Defic Syndr* 2009. [Epub ahead of print]
22. Hruz P, Zinkernagel AS, Jenikova G, Botwin GJ, Hugot JP, Karin M, Nizet V, Eckmann L. NOD2 contributes to cutaneous defense against *Staphylococcus aureus* through alpha-toxin-dependent innate immune activation. *Proc Natl Acad Sci U S A* 2009;106(31):12873-8.
23. Joos B, Rieder P, Fischer M, Kuster H, Rusert P, Trkola A, Pillai SK, Wong JK, Weber R, Gunthard HF. Association between specific HIV-1 Env traits and virologic control in vivo. *Infect Genet Evol* 2009. [Epub ahead of print]
24. Keiser O, Spoerri A, Brinkhof MW, Hasse B, Gayet-Ageron A, Tissot F, Christen A, Battegay M, Schmid P, Bernasconi E, Egger M. Suicide in HIV-Infected Individuals and the General Population in Switzerland, 1988-2008. *Am J Psychiatry* 2009. [Epub ahead of print]
25. Khanna N, Elzi L, Mueller NJ, Garzoni C, Cavassini M, Fux CA, Vernazza P, Bernasconi E, Battegay M, Hirsch HH. Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study. *Clin Infect Dis* 2009;48(10):1459-66.
26. Khanna N, Wolbers M, Mueller NJ, Garzoni C, Du Pasquier RA, Fux CA, Vernazza P, Bernasconi E, Viscidi R, Battegay M, Hirsch HH. JC virus-specific immune responses in human immunodeficiency virus type 1 patients with progressive multifocal leukoencephalopathy. *J Virol* 2009;83(9):4404-11.
27. Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, Calmy A, Mueller NJ, Muellhaupt B, Weber R. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. *Clin Infect Dis* 2009;49(4):626-35.
28. Mann AM, Rusert P, Berlinger L, Kuster H, Gunthard HF, Trkola A. HIV sensitivity to neutralization is determined by target and virus producer cell properties. *AIDS* 2009;23(13):1659-67.
29. Metzner KJ, Giulieri SG, Knoepfel SA, Rauch P, Burgisser P, Yerly S, Gunthard HF, Cavassini M. Minority quasiespecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. *Clin Infect Dis* 2009;48(2):239-47.
30. Mueller NJ, Weisser M, Fehr T, Wuthrich RP, Mullhaupt B, Lehmann R, Imhof A, Aubert JD, Genoni M, Kunz R, Weber M, Steiger J. Donor-derived aspergillosis from use of a solid organ recipient as a multiorgan donor. *Transpl Infect Dis* 2009. [Epub ahead of print]
31. Muller V, von Wyl V, Yerly S, Boni J, Klimkait T, Burgisser P, Ledergerber B, Gunthard HF, Bonhoeffer S. African descent is associated with slower CD4 cell count decline in treatment-naive patients of the Swiss HIV Cohort Study. *AIDS* 2009;23(10):1269-76.

32. Navarini AA, Lang KS, Verschoor A, Recher M, Zinkernagel AS, Nizet V, Odermatt B, Hengartner H, Zinkernagel RM. Innate immune-induced depletion of bone marrow neutrophils aggravates systemic bacterial infections. *Proc Natl Acad Sci U S A* 2009;106(17):7107-12.
33. Opravil M, Klimkait T, Louvel S, Wolf E, Battegay M, Fux CA, Bernasconi E, Vogel M, Speck R, Weber R. Prior Therapy Influences the Efficacy of Lamivudine Monotherapy in Patients with Lamivudine-resistant HIV-1 Infection. *J Acquir Immune Defic Syndr* 2009. [Epub ahead of print]
34. Peters L, Mocroft A, Soriano V, Rockstroh JK, Losso M, Valerio L, Aldins P, Reiss P, Ledergerber B, Lundgren JD. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. *J Acquir Immune Defic Syndr* 2009;50(5):457-63.
35. Rauch A, James I, Pfafferott K, Nolan D, Klenerman P, Cheng W, Mollison L, McCaughan G, Shackel N, Jeffrey GP, Baker R, Freitas E, Humphreys I, Furrer H, Gunthard HF, Hirschel B, Mallal S, John M, Lucas M, Barnes E, Gaudieri S. Divergent adaptation of hepatitis C virus genotypes 1 and 3 to human leukocyte antigen-restricted immune pressure. *Hepatology* 2009;50(4):1017-29.
36. Rotger M, Bayard C, Taffe P, Martinez R, Cavassini M, Bernasconi E, Battegay M, Hirschel B, Furrer H, Witteck A, Weber R, Ledergerber B, Telenti A, Tarr PE. Contribution of genome-wide significant single-nucleotide polymorphisms and antiretroviral therapy to dyslipidemia in HIV-infected individuals: a longitudinal study. *Circ Cardiovasc Genet* 2009;2(6):621-8.
37. Ruef C, Ruef SA, Senn G, Cathomas A, Imhof A. Decolonisation of patients with wounds colonised by MRSA. *J Hosp Infect* 2009;72(1):88-90.
38. Rusert P, Mann A, Huber M, von Wyl V, Gunthard HF, Trkola A. Divergent effects of cell environment on HIV entry inhibitor activity. *AIDS* 2009;23(11):1319-27.
39. Saxer F, Widmer A, Fehr J, Soka I, Kibatata P, Urassa H, Frei R, Smith T, Hatz C. Benefit of a single preoperative dose of antibiotics in a sub-saharan district hospital: minimal input, massive impact. *Ann Surg* 2009;249(2):322-6.
40. Scherrer AU, Hasse B, von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, Bucher HC, Ledergerber B, Gunthard HF. Prevalence of etravirine mutations and impact on response to treatment in routine clinical care: the Swiss HIV Cohort Study (SHCS). *HIV Med* 2009;10(10):647-56.
41. Scherrer AU, von Wyl V, Fux CA, Opravil M, Bucher HC, Fayet A, Decosterd LA, Hirschel B, Khanlari B, Yerly S, Klimkait T, Furrer H, Ledergerber B, Gunthard HF. Implementation of Raltegravir in Routine Clinical Practice: Selection Criteria for Choosing This Drug, Virologic Response Rates, and Characteristics of Failures. *J Acquir Immune Defic Syndr* 2009. [Epub ahead of print]
42. Schneeberger AG, Gilbert MK, Sheikh R, Gerber C, Ruef C. Non-purulent low-grade infection as cause of pain following shoulder surgery: preliminary results. *Chir Organi Mov* 2009;93 Suppl 1:S71-7.

43. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, Funk MJ, Geskus RB, Gill J, Dabis F, Miro JM, Justice AC, Ledergerber B, Fatkenheuer G, Hogg RS, Monforte AD, Saag M, Smith C, Staszewski S, Egger M, Cole SR. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. *Lancet* 2009;373(9672):1352-63.
44. Tschochner M, Chopra A, Maiden TM, Ahmad IF, James I, Furrer H, Gunthard HF, Mallal S, Rauch A, John M. Effects of HIV type-1 immune selection on susceptibility to integrase inhibitor resistance. *Antivir Ther* 2009;14(7):953-64.
45. von Wyl V, Yerly S, Burgisser P, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Francioli P, Bonhoeffer S, Ledergerber B, Gunthard HF, Swiss HIVCS. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. *Clin Infect Dis* 2009;48(7):979-87.
46. Weber R, Huber M, Rickenbach M, Furrer H, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Ledergerber B. Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. *HIV Med* 2009;10(7):407-16.
47. Worm SW, De Wit S, Weber R, Sabin CA, Reiss P, El-Sadr W, Monforte AD, Kirk O, Fontas E, Dabis F, Law MG, Lundgren JD, Friis-Moller N. Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). *Circulation* 2009;119(6):805-11.
48. Yerly S, Junier T, Gayet-Ageron A, Amari EB, von Wyl V, Gunthard HF, Hirschel B, Zdobnov E, Kaiser L. The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection. *AIDS* 2009;23(11):1415-23.
49. Young J, Bucher HC, Guenthard HF, Rickenbach M, Fux CA, Hirschel B, Cavassini M, Vernazza P, Bernasconi E, Battegay M. Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. *Antivir Ther* 2009;14(6):771-9.
50. Yukl S, Pillai S, Li P, Chang K, Pasutti W, Ahlgren C, Havlir D, Strain M, Gunthard H, Richman D, Rice AP, Daar E, Little S, Wong JK. Latently-infected CD4+ T cells are enriched for HIV-1 Tat variants with impaired transactivation activity. *Virology* 2009;387(1):98-108.
51. Zingg W, Demartines N, Imhof A, Senn G, Ruef C. Rapid colonization with methicillin-resistant coagulase-negative staphylococci after surgery. *World J Surg* 2009;33(10):2058-62.
52. Zingg W, Imhof A, Maggiorini M, Stocker R, Keller E, Ruef C. Impact of a prevention strategy targeting hand hygiene and catheter care on the incidence of catheter-related bloodstream infections. *Crit Care Med* 2009;37(7):2167-73; quiz 2180.

53. Znoj HJ, Messerli-Burgy N, Tschopp S, Weber R, Christen L, Christen S, Grawe K. Psychotherapeutic process of cognitive-behavioral intervention in HIV-infected persons: Results from a controlled, randomized prospective clinical trial. *Psychother Res* 2009;1-11.
54. Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Gill J, Fätkenheuer G, Lewden C, Saag M, Staszewski S, d'Arminio Monforte A, Casabona J, Lampe F, Justice A, von Wyl V, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. *Int J Epidemiol* 2009;38(6):1624-33.

### **Case Reports**

1. Cusini A, Günthard H, Weber R, Huber M, Kamarashev J, Bertisch B, Peter S, Beck B. Lepromatous leprosy with erythema nodosum leprosum as immune reconstitution inflammatory syndrome in an HIV-1-infected patient after initiation of antiretroviral therapy. *BMJ Case Reports* 2009.
2. Georgi A, Schneemann M, Tintelnot K, Calligaris-Maibach RC, Meyer S, Weber R, Bosshard PP. *Cryptococcus gattii* meningoencephalitis in an immunocompetent person thirteen months after exposure. *Infection* 2009;37:370-3.
3. Günthard HF, Huber M, Kuster H, Shah C, Schupbach J, Trkola A, Boni J. HIV-1 superinfection in an HIV-2-infected woman with subsequent control of HIV-1 plasma viremia. *Clin Infect Dis* 2009;48(11):e117-20.
4. Haubitz S, Saur M, Weber R. Fieber bei Reiserückkehrern: Praktische Ratschläge zu einem effizienten Abklärungsgang. *CME Online-Fortbildung. PRAXIS* 2009;98:303-311.
5. Herold MA, Kuhne R, Vosberg M, Ostheeren-Michaelis S, Vogt P, Karrer U. Disseminated toxoplasmosis in a patient with non-hodgkin lymphoma. *Infection* 2009;37(6):551-4.
6. Huber M, Knönagel H. Der besondere Nierenstein. *Schweiz Med Forum* 2009;9(5):107-108.
7. Schihin P, Iliakis D, Karrer U. [Suspected meningitis in adults]. *Praxis (Bern 1994)* 2009;98(16):859-70; quiz 871-2.
8. Weber E, Günthard HF, Schertler T, Seebach JD. Spontaneous splenic rupture as manifestation of the immune reconstitution inflammatory syndrome in an HIV type 1 infected patient with tuberculosis. *Infection*. 2009 Apr;37(2):163-5.

### **Übersichtsartikel / Reviews**

1. Gupta RK, Hill A, Sawyer AW, Cozzi-Lepri A, von Wyl V, Yerly S, Lima VD, Günthard HF, Gilks C, Pillay D. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. *Lancet Infect Dis* 2009;9(7):409-17.

2. Hofer U, Speck RF. Disturbance of the gut-associated lymphoid tissue is associated with disease progression in chronic HIV infection. *Semin Immunopathol* 2009;31(2):257-66.
3. Johnson VA, Brun-Vezinet F, Clotet B, Günthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the drug resistance mutations in HIV-1: December 2009. *Top HIV Med* 2009;17(5):138-45.
4. Karrer U, Mekker A, Wanke K, Tchang V, Haeberli L. Cytomegalovirus and immune senescence: culprit or innocent bystander? *Exp Gerontol* 2009;44(11):689-94.
5. Koller M, van Delden C, Pascual M, Müller N. Die Schweizerische Transplantationskohortenstudie (STCS). *Schweiz. Ärztezeitung* 2009;24:953-955.
6. Müller N. Infektionen und Autoimmunerkrankungen. Eine neue Rolle für Vitamin D? *Schweizer Zeitschrift für Ernährungsmedizin* 2009;2:18-21.

### **Editorials**

1. Ruef C. Influenza moves to the front of public health concerns. *Infection* 2009;37(3):185.
2. Ruef C. Hand hygiene: adherence influenced by knowledge and subjective norms. *Infection* 2009;37(4):295.
3. Ruef C. Clinical and Epidemiological Features of Tularemia. *Infection* 2009. [Epub ahead of print]

### **Andere Arbeiten**

1. Georgi AK, Ruef C, Rampini SK. [Needlestick injury--risk and prevention of blood borne infections]. *Praxis (Bern 1994)* 2009;98(20):1119-27, 1129; quiz 1128.
2. Günthard H, Kamber R. Heilung von HIV: Wo stehen wir heute? *Swiss Aids News*. 2009;2:4-7.
3. Günthard, HF(Panel member). European HIV Drug Resistance Guidelines 2009 update. The European HIV Drug Resistance Guidelines Panel, 2009. <http://www.europeanaidsclicinalsociety.org/guidelines.asp> )
4. Isler M, Huber M, Günthard H, Böni J. Negativer HIV-CombiteSt trotz hoher HIV-1 Virämie bei einem Patienten mit akuter HIV-Infektion. *Schweiz Med Forum*. 2009;9:87-8.
5. Mueller NJ, Ezzelarab M, Buhler L, Haeberli L, Ayares D, Cooper DK. Monitoring of porcine and baboon cytomegalovirus infection in xenotransplantation. *Xenotransplantation* 2009;16(6):535-6.

### **Habilitationen**

1. Metzner, KJ. Genomic diversity and population dynamics of simian and human immunodeficiency viruses (SIV/HIV). Erteilung der venia legendi für das Gebiet Experimentelle Infektiologie. Umhabilitation an der Universität Zürich, 2009

### **Dissertationen**

1. Ghielmetti, M. Human Leukocyte Recruitment to the Porcine Endothelium: Implications for Xenotransplantation. Dissertation an der ETH Zürich, 2009
2. Hübner, V. Case Control Study on Risk Factors for and Clinical Outcome of Infections with Extended Spectrum Beta-Lactamase Producing Escherichia coli and Klebsiella pneumoniae in Zürich, Switzerland 2005-2007. Dissertation an der Universität Zürich, 2009.
3. Miller, R. The Role of SOCS in HIV Infection. Dissertation an der Universität Zürich, 2009.
4. Walti, R. Epidemiologie und Klinik der Enterokokkenbakteriämie am Universitätsspital Zürich. Dissertation an der Universität Zürich, 2009

### **Masterarbeiten / Diplomarbeiten**

1. Blaser, F. Role of HIV-induced host cellular factors in HIV replication. Diplomarbeit an der Universität Zürich, 2009